Fungazol(Ketoconazole)

Quick links

Choose a section

Quick links to important sections

Advertisements

Fungazol(Ketoconazole)

Advertisements
Advertisements

Overview of Fungazol(Ketoconazole)

What Type of Medicine is Fungazol (Ketoconazole)?

Fungazol is a medicinal preparation containing the active compound Ketoconazole, which is classified as a synthetic broad-spectrum antifungal agent. The substance Ketoconazole is specifically an imidazole derivative, positioning it within the larger family of azole antifungal agents. This chemical classification dictates its pharmacological capability: selectively targeting and inhibiting the growth of fungal and yeast organisms. The compound is historically recognized as the first orally active azole capable of treating systemic fungal infections, a property established through its pharmacological development. This distinction highlights a differentiating factor within the azole class: while many early imidazoles were restricted to topical use, Ketoconazole offered a route for addressing more widespread mycoses.

Composition and Available Forms of Ketoconazole

The active agent in Fungazol is Ketoconazole, and the product is developed as a single-ingredient product. The medicine is made available in diverse dosage forms to suit different infection types and locations, utilizing two main routes of administration. These include oral forms, such as tablets, which allow the active ingredient to be absorbed systemically, and topical forms, including preparations like cream, shampoo, foam, and gel. The versatility of the oral and topical options allows for targeting whether the infection is internal or localized on the skin surface. The overall purpose of all formulations is to provide a fungistatic action, halting the proliferation of susceptible fungal organisms; for example, the shampoo form is a standardized formulation used to manage conditions like severe dandruff by suppressing the causative Malassezia fungus.

Regulatory References

  1. MedlinePlus Drug Information
Advertisements

What side effects are possible with Fungazol(Ketoconazole)?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse effects and safety constraints for Ketoconazole, based strictly on government regulatory documents (such as the FDA Prescribing Information and the EMA Summary of Product Characteristics).


Safety Profile for Oral Tablets (Systemic Use)

The systemic (tablet) form of Ketoconazole is associated with serious regulatory warnings regarding two major safety domains:

  • Serious Adverse Reactions: The official label highlights the potential for Hepatotoxicity (severe liver injury, including fatal cases) and the risk of serious Cardiac Arrhythmias (heart rhythm problems, such as QT Prolongation), often due to interactions. These risks necessitate strict limitations on use.
  • Common Adverse Reactions: Commonly reported effects across various system-organ classes include Gastrointestinal Disorders (e.g., Nausea, Vomiting, Diarrhea) and Nervous System Disorders (e.g., Headache, Dizziness).
  • Safety Constraints: The oral form is Contraindicated in patients with acute or chronic liver disease. It is also not established for use in children under two years of age.

Safety Profile for Topical Forms (Cream, Shampoo, Gel)

Topical forms are associated with localized risks, as systemic absorption is typically negligible. The serious systemic risks seen with the oral form have generally not been observed with topical use.

Frequency Classification System/Organ Class Adverse Reactions
Common Skin and Subcutaneous Tissue Skin burning sensation, Application site pruritus (itching), Application site erythema (redness)
Uncommon Immune System/Skin Hypersensitivity, Contact dermatitis, Rash
  • Safety Notes: The topical forms are not for ophthalmic use. Safety and effectiveness in older children (pediatrics) are not established in all regions.
Advertisements

Overdose and Emergency Response

Overdose with Fungazol (Ketoconazole) tablets can lead to significant systemic effects, and regulators mandate immediate medical attention be sought for any suspected ingestion beyond the prescribed amount. Documented clinical manifestations of overdose include signs of acute liver injury, such as jaundice, as well as general symptoms like anorexia, fatigue, nausea, and vomiting.

The official profile classifies overdose as potentially severe due to risks including serious hepatotoxicity, which may result in fatal outcomes, and cardiac conduction abnormalities like QT interval prolongation, which can lead to life-threatening ventricular dysrhythmias. The overdose profile is structured around these acute systemic risks.

When overdose is suspected, contacting emergency services or a Poison Control Center is required. Management focuses on supportive care and symptomatic measures. For acute oral ingestion, the procedure may include gastric lavage and activated charcoal if administered within one hour of the event. Furthermore, specific intervention is described for potential adrenal insufficiency, which involves the administration of hydrocortisone. Continuous monitoring of vital signs, fluid balance, and ECG is also an officially required part of post-overdose care. No specific antidote is explicitly listed in regulatory information. Excessive topical use may result only in temporary localized erythema or a burning sensation.

Advertisements

Therapeutic Uses of Fungazol(Ketoconazole)

What Fungazol (Ketoconazole) Treats: Main Uses and Benefits

Fungazol is commonly used to address symptom clusters related to inflammatory or irritative states associated with certain fungal and yeast overgrowth, and is considered relevant in conditions characterized by periods of heightened symptoms. This application is particularly common in its topical preparations.

The therapeutic domains are relevant for symptoms that may become disruptive, such as the persistent flaking, scaling, itching, and redness associated with seborrheic dermatitis and severe dandruff. It is also relevant for superficial fungal infections such as Tinea (Ringworm, Athlete's Foot, Jock Itch) and Pityriasis Versicolor. In highly specific, restricted clinical settings, oral forms may be part of symptomatic management in situations where patients experience severe endemic fungal diseases like Coccidioidomycosis.

“This medication is applied in scenarios where additional management of discomfort is required, offering symptomatic relief for disruptive skin manifestations.”

This supportive relief helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms, and may assist with maintaining functional stability.


Quick Fact: Relief for Itching and Scaling Fungazol is commonly used to help manage the uncomfortable itching and visible scaling that characterize common chronic conditions like seborrheic dermatitis.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Fungazol (Ketoconazole)?

The official eligibility profile for Ketoconazole is strictly defined by regulatory documents, distinguishing sharply between the highly restricted oral tablets and the less restricted topical forms.

Eligibility Scope

  • Populations for whom use is allowed (as stated in label): The general adult population for topical forms. Adults with severe endemic fungal infections, but only when alternative antifungal therapies are not available or tolerated (oral use).

  • Populations for whom use is contraindicated:

    • Known hypersensitivity to Ketoconazole or any excipients.
    • Patients with acute or chronic liver disease (oral tablets).
    • Patients concurrently taking certain medications that prolong the QTc interval (oral tablets).
    • Pregnant and breastfeeding patients (oral tablets).

Condition-Specific Eligibility Rules

Classification Rule (Oral Tablets)
Hepatic Impairment Absolute contraindication in patients with liver disease.
Cardiovascular Contraindicated in congenital or acquired QTc prolongation.

Age-Related Eligibility Status

  • Pediatric (Oral): Generally not recommended or contraindicated in children under 16 years of age.
  • Pediatric (Topical): Safety and effectiveness are often not established for children under 12 years of age.

This regulatory structure limits oral use to highly restricted, supervised settings while permitting the use of topical forms during physiological states like pregnancy and lactation due to minimal systemic absorption.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oral Ketoconazole (Fungazol tablets) has a broad and officially documented interaction profile, primarily due to its designation as a potent inhibitor of Cytochrome P450 3A4 (CYP3A4) and the efflux pumps P-glycoprotein (P-gp) and BCRP. This mechanism can significantly increase the plasma concentration of co-administered medicines.

Contraindicated Combinations

Co-administration with numerous medicines is formally contraindicated in regulatory documents. This prohibition is due to the risk of severe or life-threatening adverse reactions resulting from increased systemic exposure. Prohibited classes include certain antiarrhythmics (e.g., dofetilide, quinidine), lipid-lowering agents (e.g., simvastatin, lovastatin), and specific sedatives/anxiolytics (e.g., oral midazolam, oral triazolam). Ergot derivatives are also contraindicated due to the risk of ergotism.

Administration and Substance Constraints

Administration is subject to constraints based on external substances. Alcohol consumption must be avoided due to an officially documented increased risk of hepatotoxicity. Absorption of Ketoconazole is highly dependent on an acidic environment; therefore, acid-neutralizing medicines (e.g., antacids) must be administered at least 1 hour before or 2 hours after the Ketoconazole dose. Potent CYP3A4 inducers (e.g., rifampin) are generally not recommended as they can reduce Ketoconazole’s systemic exposure.

Population Considerations

Official labeling notes increased interaction risk/severity for certain agents in patients with severe renal impairment (e.g., colchicine, clarithromycin) and an increased risk with vardenafil in men older than 75 years.

Advertisements

Mechanism of Action

How Fungazol (Ketoconazole) Works

Fungazol's core action is strictly mechanistic, focused on the target fungal organism. The drug functions as an inhibitor of the enzyme lanosterol 14alpha-demethylase (L14DM), which is a cytochrome P450 enzyme essential to the fungal metabolic pathway.

This specific inhibition prevents the conversion of lanosterol into ergosterol, the primary sterol required for maintaining the integrity and fluidity of the fungal cell's plasma membrane. The dual consequence of this blocked pathway is the accumulation of toxic methylated sterols and a critical deficiency of ergosterol in the fungal membrane.

This structural instability causes the fungal membrane to become excessively hyper-permeable, leading to the uncontrolled efflux of essential intracellular components and a loss of cellular homeostasis. The resulting metabolic collapse and subsequent lysis (rupture) of the fungal cell leads to the observed changes in fungal cell viability and growth.

Advertisements

Dosage and Administration Information

How to Use Fungazol (Ketoconazole): Administration Guidelines

The usage of Ketoconazole is divided by the specified route of administration and the condition being managed. The medicine is available in oral tablets for systemic use and in topical forms (cream, shampoo, gel) for localized dermatologic conditions.

Oral Tablet Administration

Oral tablets are typically administered as a starting dose of 200 mg once daily for systemic fungal infections, with the option to increase to 400 mg daily based on clinical guidelines. Oral administration is recommended to be taken with food to facilitate absorption. The tablet requires an acidic environment for proper dissolution, and a special procedural instruction exists for patients with achlorhydria, involving dissolving the tablet in an acidic solution. When co-administering with acid-reducing medications, the latter should be taken at least 2 hours after the Ketoconazole tablet.

Topical Administration and Duration

The topical 2% cream is generally applied once daily; for instance, treating Tinea pedis requires a course duration of up to six weeks, while Tinea corporis typically requires two weeks. The topical shampoo is commonly used twice weekly for the initial treatment of seborrheic dermatitis. When using the shampoo, it must be applied to the affected area, lathered, left in place for five minutes, and then rinsed thoroughly. Population-specific rules include using weight-based dosing for pediatric oral use (children 2 years of age and older) and a minimum age of 12 for the topical foam/gel.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Fungazol (Ketoconazole)

Evidence for Use in Topical Skin and Scalp Conditions

This section will summarize the type and quality of research (primarily short-term Randomized Controlled Trials or RCTs) that examined the use of Ketoconazole creams, shampoos, and gels for common fungal conditions on the skin and scalp, such as seborrheic dermatitis and tinea.

Research on Seborrheic Dermatitis and Severe Dandruff

Research exploring how symptoms change over time for conditions characterized by fluctuating or episodic manifestations, such as seborrheic dermatitis (severe dandruff), primarily involved short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over defined time intervals. Trials were designed to assess the outcomes when using the active formulations versus an inactive base (placebo) or versus other specific comparative agents.

Studies monitored outcomes linked to inflammatory or irritative states, specifically measuring changes in symptoms like scaling, redness (erythema), and itching (pruritus), using standardized medical assessment scales. The research also examined mycological endpoints to evaluate patterns related to the presence of the Malassezia yeast. Research highlights changes measured during the study period, with observed outcomes often being short-term and primarily involving adult and adolescent populations.

Research on Superficial Tinea Infections and Pityriasis Versicolor

Ketoconazole was studied for conditions involving periods of heightened symptoms, such as superficial Tinea infections (like athlete’s foot or ringworm) and Pityriasis Versicolor. Research explored short-term symptom changes primarily through randomized, controlled studies. Studies monitored clinical clearance endpoints (visible resolution of symptoms) and mycological clearance endpoints (laboratory findings of fungal reduction) in adult patients with localized infections. Studies report how symptoms evolved in the observed populations, and the research described patterns related to combined clearance status following the defined application period.

Evidence for Use in Systemic Fungal Infections (Oral Tablets)

The oral tablet form of Ketoconazole was studied for severe endemic systemic fungal diseases. The research supporting this use consisted mainly of older clinical investigations and non-comparative open-label studies, which provided context but not individual predictions. Studies monitored outcomes related to systemic or functional imbalance, such as evidence of infection resolution in tissues. Current certainty remains low because the evidence quality varies across studies, and the data do not adhere to modern standards required for demonstrating efficacy.

What is Still Uncertain About the Research Base

There is limited information for long-term outcomes, especially concerning the optimal approach for monitoring symptom recurrence for chronic conditions like seborrheic dermatitis. The evidence quality varies across studies, and subgroup findings are uncertain for several populations. For the oral tablet, data show patterns related to systemic response in older, non-comparative trials, but evidence quality is limited compared to modern expectations for systemic antifungals. Research does not determine whether an individual will respond similarly, and the evidence base for efficacy is generally considered insufficient, particularly when weighed against the documented systemic risks.

Key Studies & References

  1. European Medicines Agency (EMA) Assessment Report on Ketoconazole Systemic Use
  2. NLM PubChem Substance Record: Ketoconazole
  3. MedlinePlus Drug Information: Ketoconazole Topical
  4. Systematic Review of Randomized Controlled Trials on Ketoconazole for Tinea Versicolor
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Fungazol(Ketoconazole) (FAQ)


Q: What is the main difference between Fungazol (Ketoconazole) cream and the shampoo form?

A: The official product information describes the cream as a semi-solid preparation for treating specific, localized skin infections. The shampoo, conversely, is a liquid designed for managing conditions on the scalp or larger skin areas. These different formulations have distinct methods of application and required contact times, such as lathering the shampoo and leaving it in place for several minutes before rinsing.

Q: Why is Fungazol (Ketoconazole) sometimes prescribed for uses that seem unrelated to athlete's foot?

A: Official regulatory labels state that Ketoconazole is used to treat a variety of fungal and yeast infections, not just common skin conditions. These indications include conditions like seborrheic dermatitis and pityriasis versicolor. For the oral tablet form, it is reserved for specific severe endemic fungal diseases when other treatment options are unavailable or not tolerated.

Q: Does Fungazol (Ketoconazole) start working right away, or does it take a few days?

A: Studies and official information indicate that full symptom improvement for most fungal skin infections often becomes apparent within 2 to 3 weeks of consistent use. Ketoconazole is described as fungistatic, meaning its core action is to stop the growth of the fungus, and this process takes time to result in visible clinical change.

Q: Is it true that Ketoconazole can interact with certain types of heart medications?

A: Yes, regulatory warnings explicitly state that the oral tablet form of Ketoconazole is formally contraindicated with several heart-related medicines. This prohibition is due to the potential for the interaction to cause serious and life-threatening heart rhythm problems, such as QT prolongation.

Q: Can Fungazol (Ketoconazole) be used to treat fungal infections on the scalp?

A: Yes, official labeling confirms that the shampoo formulation is specifically intended for managing certain fungal conditions that affect the scalp. This includes conditions like seborrheic dermatitis, which is a common cause of severe dandruff caused by a susceptible fungus.

Q: Are there any specific foods or drinks that should be avoided while using Fungazol (Ketoconazole)?

A: Regulatory documents strongly advise against consuming alcohol when taking the oral tablet form. This is due to a formally documented increased risk of liver toxicity (hepatotoxicity), which is a serious side effect. No official warnings restrict specific foods, although the oral tablet is instructed to be taken with food to help its absorption.

Q: What if I forget to use a dose of Fungazol (Ketoconazole) cream?

A: Patient information from official sources indicates that if a dose of the topical form is missed, the usual guidance is to resume the regular routine at the next scheduled time. The information generally advises against applying extra medicine to make up for the dose.

Q: Does the strength of Fungazol (Ketoconazole) matter for how quickly it relieves symptoms?

A: Official documents do not contain direct information comparing the speed of symptom relief between different approved product strengths. However, dosage and duration of treatment are strictly specified by regulatory bodies for each concentration and dosage form as part of the regulatory guidelines for use.

Q: Is it common to feel a mild burning sensation when first applying Fungazol (Ketoconazole) topical cream?

A: Regulatory documents describe a 'skin burning sensation' as a Common adverse reaction associated with the use of the topical cream. This finding reflects what was reported in clinical trials.

Q: If I use Fungazol (Ketoconazole) for a long time, can the fungus become resistant to it?

A: Medical literature recognizes that antifungal drug resistance can sometimes develop, which is a recognized challenge in infectious disease treatment. Official health guidance emphasizes the importance of completing the full application course, as this is part of the official guidance to fully address the infection and manage recurrence patterns.

Q: Does Fungazol (Ketoconazole) have a black box warning, and what does that mean?

A: Yes, the oral tablet form of Ketoconazole carries a Boxed Warning from the FDA. This warning highlights the significant risks of serious liver injury and life-threatening heart rhythm problems due to drug interactions, and it restricts the use of the oral form to specific severe cases only.

Q: Is Ketoconazole the same drug as Miconazole or Clotrimazole, or are they different?

A: These drugs are all classified within the same family of 'azole antifungal' agents. However, Ketoconazole, Miconazole, and Clotrimazole are distinct chemical compounds, each with its own official use profile. Ketoconazole is particularly notable for having an oral tablet form with highly restrictive regulatory warnings.

Q: Does Fungazol (Ketoconazole) treat all types of fungal infections?

A: Regulatory documents classify Ketoconazole as a broad-spectrum antifungal agent. It is officially indicated for conditions caused by specific susceptible organisms, such as certain yeasts (like Malassezia) and dermatophytes (Tinea species) listed in the product label, but it is not effective against all fungal types.

Q: What happens if I accidentally swallow a small amount of Fungazol (Ketoconazole) cream or shampoo?

A: Official safety documents for the topical forms note that in the event of accidental ingestion, supportive and symptomatic measures are indicated. Guidance for the shampoo often advises against initiating measures to induce vomiting or perform gastric lavage, due to the recognized risk of aspiration.

Q: Is there a generic version of Fungazol (Ketoconazole) available?

A: Yes, official regulatory and pharmaceutical information confirms that generic versions of the active ingredient, Ketoconazole, are available. These generic products are manufactured in both oral and various topical dosage forms.

Q: Has Ketoconazole been studied in older adults (seniors)?

A: Regulatory labels note that specific studies focused solely on the effects of Ketoconazole in geriatric patients are limited. However, an increased risk of interaction when co-administering the oral tablet with the drug vardenafil was specifically noted in men over 75 years of age.

Q: Can Fungazol (Ketoconazole) cause hair loss, or is that a misunderstanding?

A: Adverse reaction data from official sources reports that hair loss (alopecia) has been observed as a potential side effect. This has been reported more often with the oral tablet form, but it has also been reported in rare cases associated with the use of the topical forms.

Q: Are there any known issues with driving or operating machinery while using Fungazol (Ketoconazole)?

A: Official drug documents for the oral form list central nervous system effects such as dizziness and headache as possible side effects. Some official patient information notes that if side effects like dizziness or lightheadedness occur, caution is indicated when performing tasks like driving or operating machinery.

Q: Is Fungazol (Ketoconazole) typically used for prevention or just for active infections?

A: Ketoconazole is primarily indicated for treating active fungal infections. However, the shampoo form is officially documented for prophylactic (preventive) use in certain chronic conditions. For example, it can be used for the long-term management of severe dandruff.

Q: What kind of evidence is there about Ketoconazole for conditions beyond skin fungi?

A: Regulatory documents confirm that the oral tablet form has approved indications for severe endemic systemic fungal diseases like blastomycosis and coccidioidomycosis. However, its use is strictly limited to situations where other effective antifungal treatments are unavailable or cannot be tolerated.

Q: Is it safe to use Fungazol (Ketoconazole) on sensitive skin areas?

A: Official safety documents do not define 'sensitive skin' but list common application site reactions such as burning, itching, and redness. Topical forms are strictly warned against ophthalmic (eye) use and are contraindicated for use on broken or inflamed skin.

Q: What are the official recommendations regarding sun exposure while using Fungazol (Ketoconazole)?

A: Regulatory documents for the oral tablets list sensitivity to light (photosensitivity) as a potential side effect. For certain conditions managed with the topical form, official guidance describes a period of use prior to sun exposure, especially if symptoms tend to recur.

Q: Is a rash from using Fungazol (Ketoconazole) a sign of a serious allergic reaction?

A: Regulatory documents list a rash as an uncommon side effect, alongside hypersensitivity reactions, which are more serious. Serious allergic reactions include symptoms like swelling or difficulty breathing. The presence of a severe skin reaction or any signs suggesting an allergy is a situation that requires a healthcare professional's evaluation.

Q: Can I use other lotions or cosmetic products on the same area where I apply Fungazol (Ketoconazole)?

A: Patient-directed information from official health bodies generally advises avoiding the simultaneous application of other topical products in the exact area where the medicine is being used. Guidance suggests that other topical products should not be applied simultaneously. A waiting period between the application of the medicine and other lotions is usually advised.

Q: What should I do if my symptoms do not improve after using Fungazol (Ketoconazole) for a week?

A: Regulatory patient instructions advise seeking professional evaluation if symptoms worsen or if they do not improve after the specified duration, often defined in the official label (e.g., 2–4 weeks for some conditions). This ensures the management protocol can be properly adjusted if no progress is observed.

Q: Can Fungazol (Ketoconazole) interact with over-the-counter pain relievers like ibuprofen?

A: While not formally contraindicated, drug interaction databases suggest caution with the oral tablets when taken alongside medicines such as ibuprofen. This is due to the oral tablet's documented risk of liver injury (hepatotoxicity), which may be increased when used with other medicines that also affect the liver.

Advertisements

How should Fungazol(Ketoconazole) be stored and disposed of?

Ketoconazole storage and disposal requirements are dictated by regulatory labeling, which specifies distinct conditions for each dosage form.

Labeled Storage Temperature Requirements Conditions and Handling Constraints
Tablets: Controlled Room Temperature (15 C to 30 C) Must be kept in a tightly closed, light-resistant container and protected from moisture.
Topical Forms: Store below 30 C (often 20 C to 25 C) Do not freeze (cream). Protect from light. Gel and foam contents are flammable; avoid fire, flame, or smoking during and immediately following application.

All forms of the medicine must be stored out of the sight and reach of children.

Disposal of unused or expired product must follow local and national regulations. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt, coffee grounds) and sealed before placing in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fungazol(Ketoconazole) found in:

A-Z Index: